###begin article-title 0
TRIM E3 Ligases Interfere with Early and Late Stages of the Retroviral Life Cycle
###end article-title 0
###begin p 1
###xml 218 223 <span type="species:ncbi:9606">human</span>
###xml 228 233 <span type="species:ncbi:10090">mouse</span>
###xml 361 391 <span type="species:ncbi:11676">human immunodeficiency virus 1</span>
###xml 393 396 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 399 420 <span type="species:ncbi:11786">murine leukemia virus</span>
###xml 422 425 <span type="species:ncbi:11786">MLV</span>
###xml 431 451 <span type="species:ncbi:11864">avian leukosis virus</span>
###xml 453 456 <span type="species:ncbi:11864?0.898989898989899">ALV</span>
###xml 489 492 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 518 521 <span type="species:ncbi:11786">MLV</span>
Members of the TRIpartite interaction Motif (TRIM) family of E3 ligases have been shown to exhibit antiviral activities. Here we report a near comprehensive screen for antiretroviral activities of 55 TRIM proteins (36 human, 19 mouse). We identified approximately20 TRIM proteins that, when transiently expressed in HEK293 cells, affect the entry or release of human immunodeficiency virus 1 (HIV), murine leukemia virus (MLV), or avian leukosis virus (ALV). While TRIM11 and 31 inhibited HIV entry, TRIM11 enhanced N-MLV entry by interfering with Ref1 restriction. Strikingly, many TRIM proteins affected late stages of the viral life cycle. Gene silencing of endogenously expressed TRIM 25, 31, and 62 inhibited viral release indicating that they play an important role at late stages of the viral life cycle. In contrast, downregulation of TRIM11 and 15 enhanced virus release suggesting that these proteins contribute to the endogenous restriction of retroviruses in cells.
###end p 1
###begin title 2
Author Summary
###end title 2
###begin title 3

###end title 3
###begin p 4
###xml 76 79 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 476 481 <span type="species:ncbi:9606">human</span>
###xml 486 491 <span type="species:ncbi:10090">mouse</span>
###xml 679 682 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 686 689 <span type="species:ncbi:11786">MLV</span>
A lot of excitement in the field of innate immunity to retroviruses such as HIV has come from the discovery of TRIM5 as a key player in cross species restriction. TRIM5 belongs to a family of E3 ligases with over 70 members, a number of which have exhibited antiviral activity. These findings have led to the hypothesis that several TRIM proteins may contribute to the innate immunity to retroviruses. In this manuscript, we systematically test the antiviral activities of 55 human and mouse TRIM proteins. The results are astonishingly complex with activities affecting both early and late stages of the retroviral life cycle. Importantly, a number of TRIM proteins that affect HIV or MLV replication upon overexpression, enhance virus entry or release when downregulated by gene silencing. These experiments suggest that additional TRIM proteins contribute to the endogenous restriction of retroviruses. Future work should focus on the identification of TRIM proteins that are upregulated specifically in response to interferons as well as the mechanisms by which the identified proteins interfere with retroviral replication.
###end p 4
###begin title 5
Introduction
###end title 5
###begin p 6
###xml 215 216 215 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040016-b001">1</xref>
###xml 217 218 217 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040016-b005">5</xref>
###xml 524 527 524 527 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fv1</italic>
###xml 622 623 622 623 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040016-b006">6</xref>
###xml 629 630 629 630 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</sup>
###xml 626 630 626 630 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fv1<sup>n</sup></italic>
###xml 747 748 747 748 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</sup>
###xml 744 748 744 748 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fv1<sup>b</sup></italic>
###xml 803 804 803 804 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040016-b007">7</xref>
###xml 1039 1040 1039 1040 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040016-b008">8</xref>
###xml 1041 1042 1041 1042 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040016-b009">9</xref>
###xml 1161 1163 1161 1163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040016-b010">10</xref>
###xml 1164 1166 1164 1166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040016-b012">12</xref>
###xml 1320 1322 1320 1322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040016-b013">13</xref>
###xml 1323 1325 1323 1325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040016-b015">15</xref>
###xml 376 382 <span type="species:ncbi:10090">murine</span>
###xml 583 588 <span type="species:ncbi:10090">mouse</span>
###xml 651 655 <span type="species:ncbi:10090">mice</span>
###xml 689 692 <span type="species:ncbi:11786">MLV</span>
###xml 696 699 <span type="species:ncbi:11786">MLV</span>
###xml 718 721 <span type="species:ncbi:11786">MLV</span>
###xml 725 728 <span type="species:ncbi:11786">MLV</span>
###xml 766 770 <span type="species:ncbi:10090">mice</span>
###xml 784 787 <span type="species:ncbi:11786">MLV</span>
###xml 798 801 <span type="species:ncbi:11786">MLV</span>
###xml 817 820 <span type="species:ncbi:11786">MLV</span>
###xml 840 845 <span type="species:ncbi:10090">mouse</span>
###xml 900 903 <span type="species:ncbi:11786">MLV</span>
###xml 1028 1031 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1108 1113 <span type="species:ncbi:10090">mouse</span>
###xml 1137 1140 <span type="species:ncbi:11786">MLV</span>
Host cells express specific proteins to interfere with the replication of retroviruses. These proteins are referred to as restriction factors and are considered to be a part of an innate or intrinsic immune system [1-5]. The interferon inducible cytidine deaminase APOBEC3G is packaged into retroviruses and exerts its antiviral effect during reverse transcription. TRIM5 and murine Fv1 belong to a class of restriction factors that interfere with virus replication before and after reverse transcription, respectively. The Fv1 gene encodes an endogenous retroviral Gag found in the mouse genome and has two main alleles [6]. Fv1n, found in NIH Swiss mice, restricts infection by B-tropic MLV (B-MLV) but not N-tropic MLV (N-MLV). In contrast, Fv1b, found in BALB/c mice, restricts N-MLV and not B-MLV [7]. NB-tropic MLV replicates in both mouse strains. The residues critical for the N-B tropism of MLV map to the retroviral capsid protein. TRIM5 was identified as a protein responsible for the species-specific restriction of HIV entry [8,9]. Moreover, TRIM5 also mediates the Ref1 restriction of specific mouse retroviruses such as N-MLV in mammalian cells [10-12]. TRIM5 binds to incoming retroviral capsids via its C-terminal B30.2 or the SPRY (SPla/RYanodine receptor) domain causing premature capsid disassembly [13-15].
###end p 6
###begin p 7
###xml 349 356 349 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="ppat-0040016-t001">Table 1</xref>
###xml 458 465 458 465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="ppat-0040016-t001">Table 1</xref>
###xml 701 703 701 703 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040016-b016">16</xref>
###xml 704 706 704 706 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040016-b017">17</xref>
TRIM5 belongs to the large family of TRIM/RBCC proteins with over 70 members. TRIM proteins display elements of a conserved modular tripartite motif structure consisting of an N-terminal E3 ubiquitin ligase RING (Really Interesting New Gene) domain followed by one or two zinc binding motifs named B-box and a predicted coiled coil (CC) region (see Table 1). The C-terminus is highly variable and contains specific domains such as the B30.2/PRY-SPRY domain (Table 1). The presence of a RING domain suggests that these proteins function as E3 ubiquitin ligases. The associated B-box and coiled coil are believed to participate in protein-protein interactions and formation of macromolecular complexes [16,17].
###end p 7
###begin p 8
TRIM Proteins Included in the Study
###end p 8
###begin p 9
###xml 106 108 106 108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040016-b018">18</xref>
###xml 147 148 147 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040016-b008">8</xref>
###xml 149 151 149 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040016-b019">19</xref>
###xml 233 235 233 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040016-b020">20</xref>
###xml 236 238 236 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040016-b023">23</xref>
###xml 420 422 420 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040016-b017">17</xref>
###xml 505 507 505 507 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040016-b017">17</xref>
###xml 490 495 <span type="species:ncbi:9606">human</span>
TRIM proteins localize to various regions within the cells and many define specific nuclear (TRIM19/PML) [18] or cytoplasmic compartments (TRIM5) [8,19]. Others such as TRIM1, 9 and 18 have been shown to associate with microtubules [20-23]. Proposed physiological roles for TRIM proteins include fundamental cellular processes such as apoptosis, transcription, differentiation, and regulation of cell cycle progression [17]. Moreover, mutations in several TRIM proteins have been linked to human disease [17].
###end p 9
###begin p 10
###xml 113 114 113 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040016-b002">2</xref>
###xml 115 116 115 116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040016-b003">3</xref>
###xml 117 119 117 119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040016-b017">17</xref>
###xml 120 122 120 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040016-b024">24</xref>
###xml 178 180 178 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040016-b012">12</xref>
###xml 532 533 532 533 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040016-b002">2</xref>
###xml 534 536 534 536 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040016-b018">18</xref>
###xml 628 630 628 630 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040016-b024">24</xref>
###xml 708 710 708 710 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040016-b025">25</xref>
###xml 711 713 711 713 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040016-b026">26</xref>
###xml 889 891 889 891 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040016-b027">27</xref>
###xml 1054 1056 1054 1056 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040016-b027">27</xref>
###xml 1201 1202 1201 1202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040016-b002">2</xref>
###xml 1338 1339 1338 1339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040016-b002">2</xref>
###xml 1340 1342 1340 1342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040016-b017">17</xref>
###xml 1343 1345 1343 1345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040016-b028">28</xref>
###xml 173 176 <span type="species:ncbi:11786">MLV</span>
###xml 344 370 <span type="species:ncbi:11276">vesicular stomatitis virus</span>
###xml 372 389 <span type="species:ncbi:11320">influenza A virus</span>
###xml 391 412 <span type="species:ncbi:10359">human cytomegalovirus</span>
###xml 437 448 <span type="species:ncbi:205488">Ebola virus</span>
###xml 469 503 <span type="species:ncbi:11623">lymphocytic choriomeningitis virus</span>
###xml 505 522 <span type="species:ncbi:11641">human foamy virus</span>
###xml 527 530 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 556 559 <span type="species:ncbi:11786">MLV</span>
###xml 699 702 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 929 941 <span type="species:ncbi:11191">Sendai virus</span>
A number of TRIM proteins besides TRIM5 and its close relatives have been shown to possess antiviral activities [2,3,17,24]. For example, TRIM1 has been shown to restrict N-MLV [12]. Broad antiviral activities have been described for TRIM19, the defining component of PML bodies in the nucleus. The list of viruses inhibited by TRIM19 includes vesicular stomatitis virus, influenza A virus, human cytomegalovirus, herpes simplex type 1, Ebola virus, Lassa fever virus, lymphocytic choriomeningitis virus, human foamy virus and HIV [2,18]. TRIM28 restricts MLV in cells of germline origin by inhibiting LTR-driven transcription [24]. TRIM22 and TRIM32 were reported to attenuate transcription of the HIV LTR [25,26]. The identification of TRIM25 as a K63 specific ubiquitin E3 ligase activating RIG-I presents direct evidence that TRIM proteins regulate innate immunity to viral infection [27]. The recognition and suppression of Sendai virus, New Castle disease virus and vesicular stomatis virus (VSV) replication by RIG-I depends on functional TRIM25 [27]. Thus, the association of several family members with antiviral activities coupled with the fact that many of them are induced by interferons [2] has led to the hypothesis that members of TRIM family proteins are a part of innate immune system to counter intracellular pathogens [2,17,28].
###end p 10
###begin p 11
###xml 119 124 <span type="species:ncbi:9606">human</span>
###xml 129 134 <span type="species:ncbi:10090">mouse</span>
To systematically test antiretroviral activities of TRIM proteins, we investigated the ability of 55 TRIM proteins (36 human, 19 mouse) to interfere with early and/or late stages of the retroviral life cycle.
###end p 11
###begin title 12
Results
###end title 12
###begin title 13
TRIM Proteins Inhibiting or Enhancing Retroviral Entry
###end title 13
###begin p 14
###xml 87 94 87 94 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="ppat-0040016-t001">Table 1</xref>
###xml 443 452 443 452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat-0040016-sg001">Figure S1</xref>
###xml 454 456 454 456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat-0040016-sg001">S1</xref>
###xml 545 554 545 554 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat-0040016-sg001">Figure S1</xref>
###xml 53 58 <span type="species:ncbi:9606">human</span>
###xml 66 71 <span type="species:ncbi:10090">mouse</span>
###xml 475 480 <span type="species:ncbi:9606">human</span>
###xml 485 490 <span type="species:ncbi:10090">mouse</span>
We screened for potential antiviral activities of 36 human and 19 mouse TRIM proteins (Table 1) by transient expression in HEK293 cells. These cells are highly permissive for most retroviruses and are easily transfectable. We first performed control experiments to verify that the transfection of 50 ng plasmids encoding TRIM proteins in a 24-well format minimally induced apoptosis and had little effect on cell viability or gene expression (Figure S1A-S1C). In the case of human and mouse TRIM11, transfected DNA levels were reduced to 10 ng (Figure S1C).
###end p 14
###begin p 15
###xml 200 208 200 208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0040016-g001">Figure 1</xref>
###xml 427 429 427 429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040016-b029">29</xref>
###xml 359 362 <span type="species:ncbi:11864?0.898989898989899">ALV</span>
###xml 364 369 <span type="species:ncbi:363745">ALV-A</span>
We then analysed the ability of the TRIM proteins to interfere with viral entry defined here as all early events in the retroviral life cycle leading up to the establishment of viral gene expression (Figure 1A). To identify activities directed specifically against incoming retroviral capsids, all viruses carried the same subgroup A envelope glycoprotein of ALV (ALV-A) and target cells expressed the cognate receptor Tva950 [29]. To guarantee a approximately90% probability of Tva950 co-expression with each TRIM protein, plasmids encoding for both proteins were co-transfected 36 h prior to initiating infection. Infection levels were determined by measuring the expression of cytoplamic GFP from integrated viral genomes.
###end p 15
###begin title 16
TRIM Proteins Inhibiting or Enhancing Retroviral Entry
###end title 16
###begin p 17
###xml 25 28 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 39 42 <span type="species:ncbi:11786">MLV</span>
###xml 62 67 <span type="species:ncbi:363745">ALV-A</span>
(A) Experimental design: HIV, N, and B-MLV viruses carried an ALV-A envelope and the target HEK293 cells expressed cognate receptor Tva950 and TRIM proteins. Effects on entry were measured at the level of gene expression using GFP as reporter.
###end p 17
###begin p 18
###xml 57 60 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 68 71 <span type="species:ncbi:11786">MLV</span>
###xml 83 86 <span type="species:ncbi:11786">MLV</span>
(B-D) Effects of TRIM protein expression on the entry of HIV (B), N-MLV (C), and B-MLV (D) shown as fold inhibition using a log2 scale with standard errors. The dotted line represents the statistically determined cut-off value.
###end p 18
###begin p 19
###xml 48 51 <span type="species:ncbi:11786">MLV</span>
(E) Ratio of fold inhibition in N- and B-tropic MLV entry.
###end p 19
###begin p 20
(F, G) Scatter plot comparing the effects on entry for one virus against another as indicated.
###end p 20
###begin p 21
###xml 117 120 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 132 135 <span type="species:ncbi:11786">MLV</span>
###xml 194 197 <span type="species:ncbi:11786">MLV</span>
(H) Effect of silencing endogenous TRIM proteins 11, 25, 31, and 62 in HeLa cells using specific or control siRNA on HIV, NB- and N-MLV entry. The ratio of fold increase in entry of N versus NB-MLV is shown to the right.
###end p 21
###begin p 22
###xml 795 796 791 792 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040016-b008">8</xref>
###xml 797 799 793 795 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040016-b010">10</xref>
###xml 800 802 796 798 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040016-b012">12</xref>
###xml 805 813 801 809 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0040016-g001">Figure 1</xref>
###xml 31 34 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 229 234 <span type="species:ncbi:363745">ALV-A</span>
###xml 662 665 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 745 750 <span type="species:ncbi:9606">human</span>
###xml 863 866 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 902 907 <span type="species:ncbi:10090">Mouse</span>
###xml 924 927 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 994 999 <span type="species:ncbi:9606">human</span>
###xml 1019 1024 <span type="species:ncbi:10090">mouse</span>
###xml 1054 1059 <span type="species:ncbi:9606">human</span>
###xml 1071 1076 <span type="species:ncbi:10090">mouse</span>
###xml 1093 1096 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
To perform an entry screen for HIV, reporter viruses were generated in HEK293 cells by transfecting HXB2DeltaEnv-GFP, an HXB2 derivative lacking envelope and encoding GFP instead of the nef gene, together with a plasmid encoding ALV-A Env. Culture supernatants were harvested 48 h later and tested for their ability to infect HEK293 cells expressing Tva950 in the presence or absence of individual TRIM protein. To evaluate the significance of the observed inhibitory and enhancing effects standard statistical analysis was employed to arrive at a cut-off of 2.5 (by adding the maximum variability between control samples and two times the standard deviations). HIV entry was potently blocked by rhesus TRIM5 (38-fold) and to a lesser extent by human TRIM5 (5-fold) confirming previous results [8,10-12] (Figure 1B). Interestingly, no other TRIM protein affected HIV entry as potently as rhesus TRIM5. Mouse TRIM8 inhibited HIV entry about 6-fold. Moderate inhibitory effects were observed for human TRIM11, 26, 31 and mouse 10, 11 and 56. Expression of human TRIM38 and mouse TRIM21 enhanced HIV entry.
###end p 22
###begin p 23
###xml 406 414 406 414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0040016-g001">Figure 1</xref>
###xml 45 48 <span type="species:ncbi:11786">MLV</span>
###xml 52 55 <span type="species:ncbi:11786">MLV</span>
###xml 153 156 <span type="species:ncbi:11786">MLV</span>
###xml 165 168 <span type="species:ncbi:11786">MLV</span>
###xml 181 186 <span type="species:ncbi:363745">ALV-A</span>
###xml 321 324 <span type="species:ncbi:11786">MLV</span>
###xml 339 342 <span type="species:ncbi:11786">MLV</span>
###xml 477 480 <span type="species:ncbi:11786">MLV</span>
###xml 488 493 <span type="species:ncbi:9606">human</span>
###xml 513 518 <span type="species:ncbi:10090">mouse</span>
###xml 557 562 <span type="species:ncbi:9606">human</span>
###xml 567 572 <span type="species:ncbi:10090">mouse</span>
###xml 591 596 <span type="species:ncbi:10090">mouse</span>
###xml 615 618 <span type="species:ncbi:11786">MLV</span>
To perform a similar experiment for N-tropic MLV (N-MLV), reporter viruses were generated in HEK293 cells by transfecting plasmids encoding for N-tropic MLV GagPol, MLV LTR-GFP and ALV-A Env. Viruses were harvested as above and the susceptibility of HEK293 cells expressing Tva receptor and individual TRIM proteins to N-MLV was tested. N-MLV was strongly inhibited by TRIM1 (15-fold) and TRIM5 (18-fold) (Figure 1C). A number of additional TRIM proteins moderately affected N-MLV entry (human TRIM25, 26 and 62; mouse TRIM8, 25, 31 and 56). Interestingly, human and mouse TRIM11 as well as mouse TRIM30 enhanced N-MLV entry (4.5-, 3- and 4.5-fold, respectively).
###end p 23
###begin p 24
###xml 73 81 73 81 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0040016-g001">Figure 1</xref>
###xml 87 88 87 88 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0040016-g001">1</xref>
###xml 640 648 640 648 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0040016-g001">Figure 1</xref>
###xml 38 41 <span type="species:ncbi:11786">MLV</span>
###xml 68 71 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 120 125 <span type="species:ncbi:9606">human</span>
###xml 134 139 <span type="species:ncbi:10090">mouse</span>
###xml 172 175 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 180 183 <span type="species:ncbi:11786">MLV</span>
###xml 262 265 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 309 312 <span type="species:ncbi:11786">MLV</span>
###xml 353 356 <span type="species:ncbi:11786">MLV</span>
###xml 362 367 <span type="species:ncbi:9606">human</span>
###xml 372 377 <span type="species:ncbi:10090">mouse</span>
###xml 386 391 <span type="species:ncbi:9606">human</span>
###xml 400 405 <span type="species:ncbi:10090">mouse</span>
###xml 417 422 <span type="species:ncbi:10090">mouse</span>
###xml 444 449 <span type="species:ncbi:9606">human</span>
###xml 479 484 <span type="species:ncbi:10090">mouse</span>
###xml 526 529 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 597 600 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 610 613 <span type="species:ncbi:11786">MLV</span>
The inhibitory pattern observed for N-MLV was largely distinct from HIV (Figure 1B and 1C). Notable exceptions included human TRIM26, mouse TRIM8 and 56 that affected both HIV and MLV. Opposite effects were observed for the TRIM11 proteins. While they inhibited HIV entry, enhancing effects were observed for MLV. TRIM proteins specifically affecting N-MLV were human and mouse TRIM25, human TRIM62, mouse TRIM31 and mouse TRIM30. In contrast, human TRIM proteins 31, 38 and the mouse proteins 10 and 21 specifically affected HIV entry. A scatter plot depicting fold inhibition in infectivity for HIV versus N-MLV summarizes these results (Figure 1F).
###end p 24
###begin p 25
###xml 111 113 111 113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040016-b010">10</xref>
###xml 114 116 114 116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040016-b012">12</xref>
###xml 307 315 307 315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0040016-g001">Figure 1</xref>
###xml 440 448 440 448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0040016-g001">Figure 1</xref>
###xml 453 454 453 454 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0040016-g001">1</xref>
###xml 714 722 714 722 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0040016-g001">Figure 1</xref>
###xml 728 729 728 729 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0040016-g001">1</xref>
###xml 38 41 <span type="species:ncbi:11786">MLV</span>
###xml 89 92 <span type="species:ncbi:11786">MLV</span>
###xml 106 109 <span type="species:ncbi:11786">MLV</span>
###xml 166 169 <span type="species:ncbi:11786">MLV</span>
###xml 220 223 <span type="species:ncbi:11786">MLV</span>
###xml 249 254 <span type="species:ncbi:9606">human</span>
###xml 296 299 <span type="species:ncbi:11786">MLV</span>
###xml 427 430 <span type="species:ncbi:11786">MLV</span>
###xml 509 514 <span type="species:ncbi:9606">human</span>
###xml 519 524 <span type="species:ncbi:10090">mouse</span>
###xml 530 535 <span type="species:ncbi:10090">mouse</span>
###xml 572 575 <span type="species:ncbi:11786">MLV</span>
###xml 599 602 <span type="species:ncbi:11786">MLV</span>
###xml 648 651 <span type="species:ncbi:11786">MLV</span>
###xml 821 826 <span type="species:ncbi:9606">human</span>
###xml 831 836 <span type="species:ncbi:10090">mouse</span>
###xml 850 855 <span type="species:ncbi:10090">mouse</span>
The interference of TRIM 1 and 5 with MLV entry is specific for capsid determinants of N-MLV but not of B-MLV [10-12]. To test which TRIM proteins are specific for N-MLV, we performed an identical entry experiment for B-MLV. As previously reported, human TRIM1 and TRIM5 exhibited no effect on B-MLV entry (Figure 1D). In contrast, the remaining TRIM proteins exhibited an inhibitory profile that resembled that observed for N-MLV (compare Figure 1D to 1C). Interestingly, the enhancing properties of TRIM11 (human and mouse) and mouse TRIM30 proteins were specific for N-MLV and not observed for B-MLV. The ratio of fold inhibition for N versus B-MLV as well as the scatter plot analysis illustrate this finding (Figure 1E and 1G). Thus, the inhibitory effects of TRIM1 and 5 as well as the enhancing effects of TRIM11 (human and mouse) and TRIM30 (mouse) strongly correlate with N-tropism.
###end p 25
###begin p 26
###xml 195 203 195 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0040016-g001">Figure 1</xref>
###xml 112 117 <span type="species:ncbi:9606">human</span>
###xml 267 270 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 334 337 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 464 467 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 540 543 <span type="species:ncbi:11786">MLV</span>
###xml 714 717 <span type="species:ncbi:11786">MLV</span>
###xml 836 841 <span type="species:ncbi:9606">human</span>
To validate critical results gained in our transient expression screen, we downregulated endogenously expressed human TRIM proteins 11, 25, 31 and 62 in HeLa cells using RNA interference (RNAi) (Figure 1H). Consistent with the inhibitory effects of TRIM 11 and 31 on HIV entry, downregulation of both proteins using siRNA facilitated HIV entry (2-3-fold). While modest, these enhancements in viral entry suggest that TRIM11 and 31 contribute to the restriction of HIV in HeLa cells. Likewise, the enhancing effect of TRIM11 expression on N-MLV entry led to a corresponding inhibition following gene downregulation of the endogenous protein (3-fold). In contrast, TRIM25 and 62 exhibited inhibitory effects against MLV viruses when overexpressed or silenced using RNAi. Thus, the transient expression screen for TRIM proteins identified human TRIM11 and TRIM31 as factors modulating retroviral entry.
###end p 26
###begin title 27
A Role for TRIM 11 in the Reduction of TRIM 5 Protein Levels
###end title 27
###begin p 28
###xml 133 141 133 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0040016-g001">Figure 1</xref>
###xml 143 144 143 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0040016-g001">1</xref>
###xml 239 247 239 247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0040016-g002">Figure 2</xref>
###xml 380 388 380 388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0040016-g001">Figure 1</xref>
###xml 587 589 587 589 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040016-b010">10</xref>
###xml 590 592 590 592 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040016-b012">12</xref>
###xml 30 33 <span type="species:ncbi:11786">MLV</span>
###xml 45 48 <span type="species:ncbi:11786">MLV</span>
###xml 101 106 <span type="species:ncbi:10090">mouse</span>
###xml 354 357 <span type="species:ncbi:11786">MLV</span>
###xml 375 378 <span type="species:ncbi:11786">MLV</span>
###xml 486 491 <span type="species:ncbi:9606">human</span>
###xml 547 552 <span type="species:ncbi:9606">human</span>
###xml 576 579 <span type="species:ncbi:11786">MLV</span>
The specific enhancement of N-MLV, but not B-MLV entry upon expression of TRIM11 proteins as well as mouse TRIM30 was unanticipated (Figure 1C-1E). These enhancing properties of TRIM11 were observed over a wide range of expression levels (Figure 2A). Silencing of endogenous TRIM11 by siRNA in HeLa or HEK293 cells led to an increase in restriction of N-MLV, but not B or NB-MLV (Figure 1H and data not shown). Together, these data suggest that TRIM11 regulates the Ref1 restriction in human cells. HEK293 cells endogenously express low levels of human TRIM5 that restricts N-MLV entry [10-12].
###end p 28
###begin title 29
TRIM11 Reduces the Protein Levels of TRIM5
###end title 29
###begin p 30
###xml 66 71 <span type="species:ncbi:9606">human</span>
###xml 93 96 <span type="species:ncbi:11786">MLV</span>
###xml 125 128 <span type="species:ncbi:11786">MLV</span>
(A) Effects of increasing amounts of transfected plasmid encoding human TRIM11 on entry of B-MLV and increasing amounts of N-MLV.
###end p 30
###begin p 31
###xml 138 141 <span type="species:ncbi:11786">MLV</span>
(B) The effects of transient expression of TRIM11 (10 ng DNA transfected), TRIM30 (50 ng DNA transfected), and empty vector (Vector) on N-MLV entry were tested in HEK293 cells treated with either control (control si) or TRIM5 specific siRNA (H5 si).
###end p 31
###begin p 32
###xml 199 204 <span type="species:ncbi:10090">mouse</span>
(C) Western blot (anti-HA serum) of HEK293 cells 48 h after transfection with plasmids encoding HA-tagged TRIM5 and either increasing amounts (ng DNA) of empty vector (pcDNA) or a plasmid expressing mouse TRIM11 (M11). Cells were treated with the proteasome inhibitor MG132 (10 muM) for 6 h prior to analysis as indicated.
###end p 32
###begin p 33
###xml 93 98 <span type="species:ncbi:9606">human</span>
###xml 164 169 <span type="species:ncbi:10090">mouse</span>
(D) An experiment as in (C) for cells expressing HA-tagged TRIM5 or TRIM15-YFP together with human TRIM11 (H11), its mutant lacking the RING domain (DeltaRING) and mouse TRIM30 (M30). The lower panel shows the parallel TRIM5 GFP-levels in cells.
###end p 33
###begin p 34
###xml 23 26 <span type="species:ncbi:11786">MLV</span>
###xml 96 101 <span type="species:ncbi:9606">human</span>
(E) Fold increase in N-MLV entry in the HeLa cells expressing either control plasmid, wild-type human TRIM11, or its RING domain mutant (DeltaRING).
###end p 34
###begin p 35
(F) TRIM11-YFP (5 ng, red) and TRIM5-CFP (50 ng, green) were transfected into HEK293 and the localization of both proteins monitored by confocal microscopy 24 h post-transfection.
###end p 35
###begin p 36
###xml 300 308 300 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0040016-g002">Figure 2</xref>
###xml 49 52 <span type="species:ncbi:11786">MLV</span>
###xml 209 212 <span type="species:ncbi:11786">MLV</span>
To test if the effects of TRIM11 and TRIM30 on N-MLV entry are due to interference with the Ref1 restriction, we silenced TRIM5 in HEK293 cells by RNAi. Indeed, the enhancing effects of TRIM11 and TRIM30 on N-MLV entry were dependent on the presence of TRIM5 and lost in response to TRIM5 silencing (Figure 2B).
###end p 36
###begin p 37
###xml 344 352 344 352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0040016-g002">Figure 2</xref>
###xml 358 359 358 359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0040016-g002">2</xref>
###xml 533 541 533 541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0040016-g002">Figure 2</xref>
###xml 547 548 547 548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0040016-g002">2</xref>
###xml 664 672 664 672 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0040016-g002">Figure 2</xref>
###xml 806 814 806 814 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0040016-g002">Figure 2</xref>
###xml 1110 1118 1110 1118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0040016-g002">Figure 2</xref>
###xml 1295 1303 1295 1303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0040016-g002">Figure 2</xref>
###xml 1564 1572 1564 1572 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0040016-g002">Figure 2</xref>
###xml 232 237 <span type="species:ncbi:10090">mouse</span>
###xml 245 250 <span type="species:ncbi:9606">human</span>
###xml 733 738 <span type="species:ncbi:9606">human</span>
###xml 792 797 <span type="species:ncbi:9606">human</span>
###xml 1150 1153 <span type="species:ncbi:11786">MLV</span>
Potentially, these proteins affect TRIM5 protein levels. To test this hypothesis for TRIM11, a plasmid encoding HA or GFP-tagged TRIM5 was co-transfected together with either empty vector or increasing amounts of a plasmid encoding mouse and or human TRIM11. TRIM5 protein levels were then examined by western blot and fluorescence microscopy (Figure 2C and 2D). Strikingly, expression of low amounts of TRIM11 led to the disappearance of TRIM5, an effect that could be delayed by treating cells with the proteasome inhibitor MG132 (Figure 2C and 2D). The reduction of TRIM5 levels as determined by western blotting corresponded with a loss of cytoplasmic bodies (Figure 2D, lower panel). The protein levels of another TRIM protein, human TRIM15, were largely unaffected by the expression of human TRIM11 (Figure 2D). Because both proteins are expressed from the same promoter, the observed reduction in TRIM5 levels is likely not explained by effects of TRIM11 on transcription. Deleting the RING domain of TRIM11 did not affect TRIM5 protein levels, indicating a functional dependence on E3 ligase activity (Figure 2D). Correspondingly, entry of N-MLV in HeLa cells was enhanced 16-fold by the expression of wild-type TRIM11, whereas TRIM11 lacking the RING domain exhibited reduced activity (Figure 2E). Together these results suggest that TRIM11 regulates the turnover of TRIM5 thereby regulating the level of Ref1 restriction in mammalian cells. The observed co-localization of TRIM11 and TRIM5 proteins to cytoplasmic bodies is consistent with such a model (Figure 2F).
###end p 37
###begin p 38
###xml 103 111 103 111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0040016-g002">Figure 2</xref>
###xml 396 405 396 405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat-0040016-sg001">Figure S1</xref>
###xml 409 411 409 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040016-b030">30</xref>
###xml 412 414 412 414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040016-b032">32</xref>
###xml 526 527 526 527 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040016-b008">8</xref>
###xml 528 530 528 530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040016-b031">31</xref>
###xml 46 51 <span type="species:ncbi:10090">mouse</span>
###xml 119 124 <span type="species:ncbi:10090">mouse</span>
###xml 245 250 <span type="species:ncbi:9606">human</span>
###xml 264 269 <span type="species:ncbi:10090">mouse</span>
###xml 417 422 <span type="species:ncbi:10090">Mouse</span>
In contrast to TRIM11 proteins, expression of mouse TRIM30 did not affect the protein levels of TRIM5 (Figure 2D). How mouse TRIM30 interferes with the Ref1 restriction remains to be determined. Interestingly, TRIM30 is the closest homologue of human TRIM5 in the mouse genome, but carries a deletion in the variable region 1 within the B30.2 domain that is critical for interaction with capsid (Figure S1D) [30-32]. Mouse TRIM30 may function as a dominant-negative protein not unlike TRIM5 proteins lacking the B30.2 domain [8,31].
###end p 38
###begin title 39
Antiviral Activities of TRIM Proteins Affecting Late Stages of Retroviral Replication
###end title 39
###begin p 40
###xml 177 185 177 185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0040016-g003">Figure 3</xref>
###xml 972 980 968 976 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0040016-g003">Figure 3</xref>
###xml 1059 1068 1055 1064 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat-0040016-sg002">Figure S2</xref>
###xml 1262 1270 1258 1266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0040016-g003">Figure 3</xref>
###xml 1678 1686 1674 1682 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0040016-g003">Figure 3</xref>
###xml 223 226 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 332 335 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 886 889 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 948 951 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1002 1005 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1099 1104 <span type="species:ncbi:9606">human</span>
###xml 1135 1140 <span type="species:ncbi:10090">mouse</span>
###xml 1207 1210 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1301 1306 <span type="species:ncbi:9606">human</span>
###xml 1326 1331 <span type="species:ncbi:10090">mouse</span>
###xml 1463 1468 <span type="species:ncbi:9606">human</span>
After studying the role of TRIM proteins during early events in viral replication, we next investigated if they exhibited antiviral effects at late stages of viral replication (Figure 3A). To determine effects specific for HIV release, we bypassed entry by directly transfecting plasmids that encoded for TRIM proteins along with a HIV variant HXB2DeltaEnv-GFP lacking Env and expressing cytoplasmic GFP. Infectious virions were generated by co-expression of VSVG. After 48 h, the culture supernatants were harvested and the level of GFP expression in producer cells was determined by flow cytometry. The viral infectivity in the harvested culture supernatant was determined by infecting susceptible target cells and measuring GFP-positive cells after an additional 36 h. In addition, the Gag protein released into the supernatant was determined by western blot using antibodies to the HIV capsid protein p24. The results of such an experiment for HIV release is shown in Figure 3B in fold inhibition. HIV capsid released into the supernatant is presented in Figure S2A. Our analysis identified the human TRIM proteins 15, 26, 32, the mouse proteins 11, 25, 27, and 56 as factors that specifically affected HIV release from cells, but not viral gene expression (Figure 3B). A number of TRIM proteins (human TRIM19, 21, 25 and mouse TRIM8) were close to the statistically determined cut-off value of 6. At the transfection level (50ng) used in the assembly assay, human TRIM11 affected both viral gene expression and virus release. A scatter plot analysis depicting the effects of TRIM protein expression on virus release over effects on LTR expression summarizes these results (Figure 3D).
###end p 40
###begin title 41
TRIM Proteins Interfering with Virus Production and Release
###end title 41
###begin p 42
###xml 91 94 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 98 101 <span type="species:ncbi:11786">MLV</span>
(A) Experimental design: HEK293 cells transfected with viral plasmids encoding full-length HIV or MLV and carrying a GFP-reporter gene in the presence or absence of plasmids encoding individual TRIM proteins. 48 h after transfection, producer cells and culture supernatants were harvested. Producer cells were subjected to FACS analysis to measure viral gene expression. The infectivity of culture supernatants was determined by infecting target cells and measuring GFP-positive cells 36 h after initiation of infection using FACS analysis.
###end p 42
###begin p 43
###xml 91 94 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 103 106 <span type="species:ncbi:11786">MLV</span>
###xml 440 443 <span type="species:ncbi:11786">MLV</span>
###xml 540 543 <span type="species:ncbi:11786">MLV</span>
(B, C) Effects of TRIM protein expression in HEK293 cells on the production and release of HIV (B) and MLV (C). Graphs represent the fold inhibition (log10 scale) in released viral infectivity (grey bars) and in viral gene expression (black bars). All experiments were performed at least in triplicates and the bars represent standard errors from the mean values. The dotted line represents the statistically determined cut-off value of 6. MLV Gag released into culture supernatant was analysed by western blot using antibodies against p30 MLV capsid and presented beneath the graph in (C). Partition lines indicate individual gels.
###end p 43
###begin p 44
###xml 190 193 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 202 205 <span type="species:ncbi:11786">MLV</span>
(D, E) Scatter plots of data shown in panels (B) and (C) depicting fold inhibitions in released virus infectivity plotted against viral gene expression from the LTR upon TRIM expression for HIV (D) and MLV (E).
###end p 44
###begin p 45
###xml 61 69 61 69 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0040016-g003">Figure 3</xref>
###xml 172 174 172 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040016-b033">33</xref>
###xml 175 177 175 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040016-b034">34</xref>
###xml 257 265 257 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0040016-g003">Figure 3</xref>
###xml 531 539 531 539 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0040016-g003">Figure 3</xref>
###xml 720 729 720 729 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat-0040016-sg002">Figure S2</xref>
###xml 56 59 <span type="species:ncbi:11786">MLV</span>
###xml 114 117 <span type="species:ncbi:11786">MLV</span>
###xml 180 183 <span type="species:ncbi:11786">MLV</span>
###xml 317 320 <span type="species:ncbi:11786">MLV</span>
###xml 371 376 <span type="species:ncbi:9606">human</span>
###xml 445 448 <span type="species:ncbi:11786">MLV</span>
###xml 496 499 <span type="species:ncbi:11786">MLV</span>
###xml 636 641 <span type="species:ncbi:9606">human</span>
###xml 665 670 <span type="species:ncbi:10090">mouse</span>
We then performed an identical experiment for NB-tropic MLV (Figure 3C) using a plasmid encoding for the Friend57 MLV genome carrying a GFP insertion into the Env protein [33,34]. MLV capsid (p30) released into the supernatant is presented below the graph (Figure 3C). Our analysis revealed a striking sensitivity of MLV to the expression of TRIM proteins, in particular human TRIM proteins. Overall, 21 TRIM proteins and rhesus TRIM5 inhibited MLV release at least 10-fold, 9 of which inhibited MLV release by more than 100-fold (Figure 3C). A dose-response experiment revealed that transfecting small amounts of plasmids encoding for human TRIM15, 25, 31, 62 and mouse 11 and 25 resulted in potent antiviral activity (Figure S2B). In contrast, higher DNA amounts were required for the other TRIM proteins, particularly TRIM5. TRIM22, while removed from the screen due to varying results, did exhibit antiviral activity in a dose-dependent manner.
###end p 45
###begin p 46
###xml 285 293 285 293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0040016-g003">Figure 3</xref>
###xml 756 764 756 764 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0040016-g003">Figure 3</xref>
###xml 58 61 <span type="species:ncbi:11786">MLV</span>
###xml 204 207 <span type="species:ncbi:11786">MLV</span>
###xml 333 338 <span type="species:ncbi:9606">human</span>
###xml 392 397 <span type="species:ncbi:10090">mouse</span>
Generally, we observed two distinct phenotypic groups for MLV restriction. The first group, including the TRIM proteins 8, 15, 19, 25, 26, 28 and 35 specifically interfered with the release of infectious MLV into the culture supernatant without major effects on viral gene expression (Figure 3C). For the second group, consisting of human TRIM proteins 1, 11, 13, 14, 21, 27, 31, 32, 62, the mouse proteins 8, 11, 27 and rhesus 5, the inhibitory effects on viral gene expression were close to the cut-off of 6 or higher implying that a suppression of viral gene expression contributed to the observed reduction in the release of infectivity. A scatter plot depicting effects of TRIM proteins on infectivity versus gene expression summarizes these results (Figure 3E).
###end p 46
###begin p 47
###xml 273 282 273 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat-0040016-sg002">Figure S2</xref>
###xml 402 404 402 404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040016-b035">35</xref>
###xml 196 201 <span type="species:ncbi:9606">human</span>
###xml 217 222 <span type="species:ncbi:10090">mouse</span>
For a number of TRIM proteins, the reduction in infectivity did not correspond with a proportionate reduction in p30 release. Western blot analysis of released virus for Env and Gag revealed that human TRIM13, 21 and mouse TRIM19 preferentially affected Env incorporation (Figure S2C). A reported role for TRIM13 in protein degradation at the endoplasmic reticulum is consistent with such a phenotype [35].
###end p 47
###begin p 48
###xml 166 168 166 168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040016-b036">36</xref>
###xml 267 276 267 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat-0040016-sg002">Figure S2</xref>
###xml 20 23 <span type="species:ncbi:11864?0.898989898989899">ALV</span>
###xml 78 85 <span type="species:ncbi:9031">chicken</span>
###xml 216 221 <span type="species:ncbi:9606">human</span>
###xml 226 231 <span type="species:ncbi:10090">mouse</span>
###xml 240 245 <span type="species:ncbi:9606">human</span>
###xml 253 258 <span type="species:ncbi:10090">mouse</span>
###xml 280 285 <span type="species:ncbi:9606">Human</span>
###xml 312 315 <span type="species:ncbi:11864?0.898989898989899">ALV</span>
Finally, to measure ALV release, we studied the effects of TRIM expression in chicken fibroblasts because the release of this virus is restricted in mammalian cells [36]. Among the few potent antiviral proteins were human and mouse TRIM25, human 32 and mouse TRIM11 (Figure S2D). Human TRIM11 was not tested for ALV.
###end p 48
###begin title 49
###xml 18 23 <span type="species:ncbi:9606">Human</span>
###xml 61 64 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 69 72 <span type="species:ncbi:11786">MLV</span>
Gene Silencing of Human TRIM Proteins 25, 31, and 62 Affects HIV and MLV Release
###end title 49
###begin p 50
###xml 404 413 404 413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat-0040016-sg003">Figure S3</xref>
###xml 419 421 419 421 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat-0040016-sg003">S3</xref>
###xml 589 597 589 597 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0040016-g004">Figure 4</xref>
###xml 603 604 603 604 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0040016-g004">4</xref>
###xml 703 711 703 711 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0040016-g004">Figure 4</xref>
###xml 810 818 810 818 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0040016-g004">Figure 4</xref>
###xml 481 484 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 489 492 <span type="species:ncbi:11786">MLV</span>
###xml 676 679 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 777 780 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
The inhibitory effects observed above could be the result of overexpression of these proteins in HEK293 cells. To determine their role in the viral life cycle, we targeted endogenously expressed TRIM proteins for downregulation using RNAi. We concentrated on TRIM 11, 15, 25, 31 and 62 because they were very effective at low transfection levels and were endogenously expressed in HEK293 and HeLa cells (Figure S3A and S3B). Downregulation of TRIM proteins 25, 31 and 62 inhibited HIV and MLV release in HEK293 cells, suggesting that these proteins play a role in efficient virus release (Figure 4A and 4B). Notably, silencing of TRIM62 also strongly interfered (7-fold) with HIV release in HeLa cells (Figure 4B). Correspondingly, expression of low amounts of TRIM62 enhanced HIV gene expression and release (Figure 4C).
###end p 50
###begin title 51
Inhibitory and Enhancing Roles of Individual TRIM Proteins on Viral Release
###end title 51
###begin p 52
###xml 24 27 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 32 35 <span type="species:ncbi:11786">MLV</span>
###xml 170 175 <span type="species:ncbi:9606">human</span>
(A, B) Fold increase in HIV and MLV infectivity released from HEK293 (A) and HeLa (B) cells treated with control siRNA (contsi) or siRNA targeting endogenously expressed human TRIM proteins 11, 15, 25, 31, and 62.
###end p 52
###begin p 53
###xml 21 24 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
(C) Fold increase in HIV gene expression and released infectivity in HEK293 cells transfected with increasing amounts of plasmid (0-100 ng) expressing TRIM62 or its E3 mutant (62E3m).
###end p 53
###begin p 54
###xml 19 22 <span type="species:ncbi:11786">MLV</span>
(D) Infectivity of MLV released from HEK293 cells is shown as fold inhibition in presence of plasmids expressing TRIM11, 15, 25, 62, or their E3 mutants (E3m).
###end p 54
###begin p 55
###xml 308 316 308 316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0040016-g004">Figure 4</xref>
###xml 322 323 322 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0040016-g004">4</xref>
###xml 186 189 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 194 197 <span type="species:ncbi:11786">MLV</span>
To gain further insights into the antiviral activities of these proteins we tested mutant proteins impaired in their E3 ligase activity. Interestingly, the E3 mutant of TRIM62 inhibited HIV and MLV release more potently than the wild-type protein, likely by exhibiting a pronounced dominant-negative effect (Figure 4C and 4D). Together, these data suggest that TRIM 25, 31 and 62 play an important role in virus release.
###end p 55
###begin title 56
###xml 70 75 <span type="species:ncbi:9606">Human</span>
TRIM11 and 15 Contribute to the Innate Restriction of Retroviruses in Human Cells
###end title 56
###begin p 57
###xml 160 168 148 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0040016-g004">Figure 4</xref>
###xml 174 175 162 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0040016-g004">4</xref>
###xml 261 269 249 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0040016-g004">Figure 4</xref>
###xml 79 82 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 179 182 <span type="species:ncbi:11786">MLV</span>
###xml 447 450 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 455 458 <span type="species:ncbi:11786">MLV</span>
In contrast to TRIM25, 31 and 62, downregulation of endogenous TRIM11 enhanced HIV release approximately4-fold in HEK293 and moderately (2xfold) in HeLa cells (Figure 4A and 4B). MLV release was enhanced 5-fold in response to silencing of TRIM15 in HeLa cells (Figure 4B). The enhancement of virus release observed in response to gene silencing is consistent with the hypothesis that both TRIM proteins contribute to the endogenous restriction of HIV and MLV in mammalian cells.
###end p 57
###begin p 58
###xml 205 213 205 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0040016-g004">Figure 4</xref>
###xml 447 455 447 455 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0040016-g004">Figure 4</xref>
We next tested the contribution of E3 ligase function to the antiviral activity of both proteins. Interestingly, the antiviral activity of TRIM11 was critically dependent on a functional E3 ligase domain (Figure 4D) implying the involvement of the ubiquitin-dependent degradative pathway. In contrast, the E3 mutant of TRIM15 largely retained its inhibitory activity indicating that it interferes with viral replication via a different mechanism (Figure 4D).
###end p 58
###begin title 59
###xml 90 93 <span type="species:ncbi:11786">MLV</span>
The Antiviral Activity of TRIM15 Depends on the Ability of its B-box to Interact with the MLV Gag Precursor Protein
###end title 59
###begin p 60
###xml 269 277 269 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0040016-g005">Figure 5</xref>
###xml 388 396 388 396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0040016-g005">Figure 5</xref>
###xml 129 134 <span type="species:ncbi:9606">human</span>
To understand how TRIM15 can interfere with viral release in an E3 ligase independent manner, we performed a domain analysis for human TRIM15. TRIM15 YFP fusion protein was as active as its untagged version. Hence this analysis was performed using YFP fusion proteins (Figure 5A). Interestingly, TRIM15 lacking the B-box, but not RING or SPRY domains, lost all of its antiviral activity (Figure 5A). In fact, the B-box alone exhibited antiviral activity.
###end p 60
###begin title 61
The Antiviral Activity of TRIM15 Resides in Its B-box
###end title 61
###begin p 62
###xml 23 26 <span type="species:ncbi:11786">MLV</span>
(A) Fold inhibition in MLV released infectivity in presence of indicated TRIM15-YFP derivatives. The vectors pcDNA or pEYFP were used as controls. Top schematic displays the TRIM15 domain structure.
###end p 62
###begin p 63
###xml 48 51 <span type="species:ncbi:11786">MLV</span>
(B) Western blot using GFP antibodies to detect MLV Gag-GFP that co-immunoprecipitated with antibodies against TRIM15.
###end p 63
###begin p 64
###xml 108 111 <span type="species:ncbi:11786">MLV</span>
(C) Western blot using antibodies to GFP to identify TRIM15-YFP derivatives that co-immunoprecipitated with MLV Gag.
###end p 64
###begin p 65
###xml 4 7 <span type="species:ncbi:11786">MLV</span>
###xml 37 40 <span type="species:ncbi:11786">MLV</span>
(D) MLV Gag-CFP (green), full length MLV and TRIM15-YFP (red) were transfected into HEK293 cells and monitored 24 h later. Green arrows indicate the accumulation of Gag at the plasma membrane. Red arrows point to cytoplasmic TRIM15 bodies.
###end p 65
###begin p 66
###xml 56 59 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
(E) An experiment as described in (D) was performed for HIV Gag-YFP (red) and TRIM15-CFP (green).
###end p 66
###begin p 67
###xml 91 93 91 93 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040016-b013">13</xref>
###xml 94 96 94 96 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040016-b015">15</xref>
###xml 229 231 229 231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040016-b037">37</xref>
###xml 445 453 445 453 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0040016-g005">Figure 5</xref>
###xml 459 460 459 460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0040016-g005">5</xref>
###xml 302 305 <span type="species:ncbi:11786">MLV</span>
###xml 421 424 <span type="species:ncbi:11786">MLV</span>
###xml 531 534 <span type="species:ncbi:11786">MLV</span>
###xml 649 652 <span type="species:ncbi:11786">MLV</span>
###xml 705 708 <span type="species:ncbi:11786">MLV</span>
###xml 755 758 <span type="species:ncbi:11786">MLV</span>
TRIM5 specifically interferes with retroviral entry by binding to incoming mature capsids [13-15] and it had recently been suggested that rhesus TRIM5 can also bind and degrade immature capsids interfering with virus production [37]. To test if TRIM15 can bind to the immature Gag precursor protein of MLV, we performed co-immunoprecipitations. Interestingly, antibodies against TRIM15 specifically co-immunoprecipitated MLV Gag and vice versa (Figure 5B and 5C). Importantly, TRIM15 fragments containing the B-box interacted with MLV Gag, while TRIM15 mutants lacking the B-box did not. In fact, the B-box alone was capable of interacting with the MLV Gag precursor protein. Thus, TRIM15 interferes with MLV release by directly or indirectly binding the MLV Gag precursor protein via its B-box.
###end p 67
###begin p 68
###xml 371 379 371 379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0040016-g005">Figure 5</xref>
###xml 555 563 555 563 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0040016-g005">Figure 5</xref>
###xml 150 153 <span type="species:ncbi:11786">MLV</span>
###xml 188 191 <span type="species:ncbi:11786">MLV</span>
###xml 478 481 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
To understand how TRIM15 binding to Gag alters the cellular fate of retroviral capsids, we transfected plasmids encoding for TRIM15-YFP together with MLV Gag-CFP and replication competent MLV into HEK293. Visualization using fluorescence microscopy revealed on average a reduction of Gag fluorescence at the plasma membrane in cells containing cytoplasmic TRIM15 bodies (Figure 5D). When TRIM15-CFP was expressed together with HIVGag-YFP, a similar phenotype was observed. Less HIV Gag reached the plasma membrane, but rather accumulated intracellularly (Figure 5E).
###end p 68
###begin title 69
Discussion
###end title 69
###begin p 70
###xml 397 398 385 386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040016-b002">2</xref>
Using a transient expression screen in HEK293 cells we have performed the first near comprehensive screen for antiviral activities of members of the TRIM family of proteins. Our screen identifies approximately20 TRIM proteins with antiviral activity demonstrating that multiple TRIM proteins can exhibit antiviral activities. Because many TRIM proteins are upregulated in response to interferons [2], a potential role of these proteins in the establishment of an antiviral state should be investigated.
###end p 70
###begin p 71
###xml 100 108 100 108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0040016-g006">Figure 6</xref>
###xml 423 431 423 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0040016-g006">Figure 6</xref>
###xml 433 434 433 434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0040016-g006">6</xref>
###xml 557 565 557 565 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0040016-g006">Figure 6</xref>
###xml 571 572 571 572 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0040016-g006">6</xref>
###xml 274 277 <span type="species:ncbi:11786">MLV</span>
###xml 498 501 <span type="species:ncbi:11786">MLV</span>
The specific effects of TRIM proteins on the replication cycle of each retrovirus are summarized in Figure 6A using red/green color-coding for inhibitory and enhancing activities, respectively. This presentation readily displays the specificity of TRIM1, 5, 11 and 30 for N-MLV entry. This analysis also allows a comparison of the entry results with the viral gene expression data obtained in the screen for virus release (Figure 6A-6C). For example, the inhibitory activities of TRIM1 and 62 on N-MLV entry likely include effects on viral gene expression (Figure 6A and 6C).
###end p 71
###begin title 72
Anti-retroviral Activities of TRIM Proteins Identified in This Study
###end title 72
###begin p 73
(A) A Java TREEVIEW graphic display of all TRIM proteins activities against early and late stages of the retroviral life cycle. Input fold inhibition values were log2 transformed and shown as red/green color-coding for inhibitory and enhancing activities, respectively. Grey stands for experiments not carried out.
###end p 73
###begin p 74
(B-D) Scatter plot analyses were performed as indicated.
###end p 74
###begin p 75
###xml 114 122 114 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0040016-g006">Figure 6</xref>
###xml 128 129 128 129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0040016-g006">6</xref>
###xml 665 667 665 667 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040016-b038">38</xref>
###xml 668 670 668 670 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040016-b039">39</xref>
###xml 53 58 <span type="species:ncbi:9606">human</span>
###xml 63 68 <span type="species:ncbi:10090">mouse</span>
###xml 93 96 <span type="species:ncbi:11786">MLV</span>
###xml 209 212 <span type="species:ncbi:11786">MLV</span>
###xml 224 227 <span type="species:ncbi:11786">MLV</span>
This analysis also reveals that an overexpression of human and mouse TRIM11 proteins affects MLV gene expression (Figure 6A and 6C). Despite these inhibitory effects, TRIM11 expression specifically enhanced N-MLV, but not B-MLV entry. Under these conditions, the protein levels of transiently expressed TRIM5 were reduced. TRIM11 may contribute to the turnover of endogenous TRIM5, because silencing of endogenous TRIM11 enhanced the Ref1 restriction. These two observed activities of TRIM11, degradation of cytoplasmic proteins as well as the regulation of transcription, are similar to previous reports for a role of TRIM11 in the turnover of humanin and ARC105 [38,39]. Clearly, several cellular targets exist for TRIM11. Its potential role in the turn over of TRIM5, a protein that potently restricts retrovirus entry, could be of therapeutic importance.
###end p 75
###begin p 76
###xml 129 137 129 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0040016-g006">Figure 6</xref>
###xml 330 338 330 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0040016-g006">Figure 6</xref>
###xml 141 144 <span type="species:ncbi:11786">MLV</span>
###xml 218 223 <span type="species:ncbi:9606">human</span>
###xml 286 289 <span type="species:ncbi:11786">MLV</span>
###xml 316 321 <span type="species:ncbi:10090">mouse</span>
###xml 390 393 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 406 411 <span type="species:ncbi:10090">mouse</span>
###xml 433 438 <span type="species:ncbi:9606">human</span>
###xml 469 472 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Strikingly, most of the antiviral TRIM proteins exhibited strong inhibitory effects against late stages of the viral life cycle (Figure 6A). MLV was highly sensitive to the expression of TRIM proteins, particularly of human origin. Of the 14 TRIM proteins specifically interfering with MLV release, only two were of mouse origin (Figure 6D). A similar cross species effect was observed for HIV. 21% of all mouse, but only 11% of all human TRIM proteins interfered with HIV release. Cross species effects are consistent with the hypothesis that TRIM proteins contribute to the innate control of retroviruses and that over time, viruses can adapt to inhibitory effects.
###end p 76
###begin p 77
In our further analysis we concentrated on TRIM proteins that were highly effective even at very low transfection levels. Gene silencing of TRIM 25, 31 and 62 inhibited virus release suggesting that these E3 ligases play a role in cellular pathways critical for virus release. They were identified in our expression screen likely because overexpression of the wild-type protein exhibited a dominant-negative effect.
###end p 77
###begin p 78
###xml 136 139 <span type="species:ncbi:11786">MLV</span>
###xml 144 147 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
In contrast, downregulation of TRIM11 and TRIM15 enhanced virus release suggesting that these proteins contribute to the restriction of MLV and HIV even in highly susceptible HEK293 and HeLa cells. A detailed understanding of host restriction may lead to antiviral therapies aimed at strengthening the innate immunity to retroviruses at the cellular level. The interaction of TRIM15 with retroviral Gag suggests that TRIM proteins, apart from entry, can recognize retroviral Gag proteins during assembly and budding and thereby inhibit viral release. A preferential targeting of late stages of the retroviral life cycle may be more consistent with a role for TRIM proteins in the establishment of an antiviral state.
###end p 78
###begin title 79
Materials and Methods
###end title 79
###begin title 80
Cell lines and plasmids.
###end title 80
###begin p 81
###xml 55 57 55 57 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040016-b040">40</xref>
###xml 159 166 159 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="ppat-0040016-t001">Table 1</xref>
###xml 264 269 <span type="species:ncbi:9606">human</span>
###xml 314 319 <span type="species:ncbi:9606">human</span>
HEK293, HeLa, DFJ8 and DF-1 were described previously [40]. TZM-bl cells were a gift from Vineet KewalRamani (NCI Frederick, MD). TRIM constructs presented in Table 1 were confirmed by sequencing to be authentic and in the correct reading frame. The reference for human TRIM22 is NM_006074. YFP fusion proteins of human TRIM 11, 15, 25, 31 and 62 were generated by insertion of PCR amplified genes into the EcoRI/XhoI sites of pEYFP-N1 (Clontech, Palo Alto, CA). E3 mutants were created by substituting two active site cysteines to alanine using site-directed mutagenesis (QuikChange, Stratagene, La Jolla, CA). TRIM15-YFP mutants were generated by PCR; BCPS, CPS, RBC, R-CPS-YFP fusions lacked the amino acids 1-64, 1-119, 346-465 and 81-119, respectively. The B-box-YFP corresponds to amino acids 64-129.
###end p 81
###begin title 82
Generation of viruses.
###end title 82
###begin p 83
###xml 106 108 105 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040016-b040">40</xref>
###xml 189 191 187 189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040016-b041">41</xref>
###xml 336 338 333 335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040016-b042">42</xref>
###xml 367 369 364 366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040016-b041">41</xref>
###xml 589 590 585 586 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 761 763 756 758 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040016-b041">41</xref>
###xml 865 867 860 862 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040016-b041">41</xref>
###xml 19 22 <span type="species:ncbi:11786">MLV</span>
###xml 177 180 <span type="species:ncbi:11864?0.898989898989899">ALV</span>
###xml 182 186 <span type="species:ncbi:11864">EnvA</span>
###xml 519 524 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 751 754 <span type="species:ncbi:11864?0.898989898989899">ALV</span>
###xml 755 759 <span type="species:ncbi:11864">EnvA</span>
###xml 766 769 <span type="species:ncbi:11864?0.898989898989899">ALV</span>
###xml 929 955 <span type="species:ncbi:11276">Vesicular stomatitis virus</span>
###xml 993 998 <span type="species:ncbi:363745">ALV-A</span>
N, B and NB-tropic MLV were prepared by transfecting 4 mug of a plasmid encoding a viral RNA (pLZRS-GFP) [40], 4 mug plasmid encoding the envelope glycoprotein of subgroup A of ALV (EnvA) [41] and 4 mug of plasmids expressing either N-, B-tropic (pCIG3-N or B, gifts from Greg Towers and Jonathan Stoye, University College London, UK) [42] or NB GagPol (pMDGag-Pol) [41] into a 10 cm plate of HEK293 cells using FuGene 6 (Roche, Indianapolis, IN, USA) and serum-free OPTIMEM media (Invitrogen Corporation, California). HIV-1 reporter viruses were generated by transfecting 4 mug of HXB2Env--GFP, a HXB2 derivative (lacking envelope and encoding GFP instead of nef gene; gift from Heinrich Gottlinger, Worcester, UMass, MA), and 4 mug plasmid encoding ALV EnvA [41]. ALV reporter viruses were from supernatants of DF-1 cells chronically infected with RCASBP(A)-GFP [41]. For siRNA experiments, viruses were generated carrying the Vesicular stomatitis virus G (VSVG) envelope protein instead of ALV-A Env. The culture medium was harvested 48 h after transfection, filtered through 0.45 mum, aliquoted and stored at -80 C. To determine the titer, serial dilutions of virus stocks were titrated onto DFJ8 cells in the presence of 5 mug/ml of polybrene followed by flow cytometry of GFP- positive cells (FACS, Becton Dickinson) 36-48 h later.
###end p 83
###begin title 84
Virus entry assays.
###end title 84
###begin p 85
###xml 220 221 220 221 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 866 874 866 874 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0040016-g001">Figure 1</xref>
###xml 1187 1195 1175 1183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0040016-g001">Figure 1</xref>
###xml 112 115 <span type="species:ncbi:11864?0.898989898989899">ALV</span>
###xml 298 301 <span type="species:ncbi:11786">MLV</span>
###xml 303 306 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 310 313 <span type="species:ncbi:11864?0.898989898989899">ALV</span>
HEK293 cells were co-transfected in 24 wells with 50 ng each of plasmids encoding the TRIM protein and 25 ng of ALV receptor Tva950. 30 h after transfection, cells were seeded into 48-well plates at a density of 1.5 x 104 target cells/well. After an additional 6 h, cells were challenged with N, B-MLV, HIV or ALV carrying a GFP reporter genome. GFP-positive cells were quantified by flow cytometry after 36 h post infection. To perform the screen initially with a dynamic range that allows reliable detection of both inhibiting and enhancing effects, an amount of virus was used that resulted in infection levels of 5%. Strong inhibitory or enhancing TRIM proteins were characterized in a second round with adjusted infection levels. All experiments were at least performed four times on separate days. These data sets were combined for the final analysis shown in Figure 1. Fold inhibitions in virus entry represent the ratio of percent GFP-positive cells of cells transfected with empty control vector versus those expressing TRIM proteins. The maximum variability between control samples in the absence of TRIM proteins was approximately1.5-fold. The cut-off value of 2.5 applied in Figure 1 was the derived from 1.5 plus two times the standard deviations (confidence value of 95%) of 0.5.
###end p 85
###begin title 86
Virus release and gene expression assays.
###end title 86
###begin p 87
###xml 8 9 8 9 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 144 145 144 145 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 328 330 328 330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040016-b033">33</xref>
###xml 331 333 331 333 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040016-b034">34</xref>
###xml 451 452 451 452 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 721 723 721 723 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040016-b033">33</xref>
###xml 1518 1526 1505 1513 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0040016-g003">Figure 3</xref>
###xml 189 192 <span type="species:ncbi:11786">MLV</span>
###xml 269 272 <span type="species:ncbi:11786">MLV</span>
###xml 395 398 <span type="species:ncbi:11864?0.898989898989899">ALV</span>
###xml 528 531 <span type="species:ncbi:11864?0.898989898989899">ALV</span>
###xml 684 687 <span type="species:ncbi:11786">MLV</span>
###xml 898 901 <span type="species:ncbi:11786">MLV</span>
###xml 906 909 <span type="species:ncbi:11864?0.898989898989899">ALV</span>
###xml 937 940 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
2.5 x 105 HEK293 cells (producer cells) in 24-wells were transfected with 50 ng TRIM expressing construct with either 150 ng each of the HXB2Env--GFP and 50 ng plasmid expressing VSVG. For MLV release assays, 200 ng of plasmid MLVEnv-GFP encoding full length Friend 57 MLV genome with a GFP insertion into the envelope protein [33,34] was co-transfected with TRIM expressing construct as above. ALV release assays were conducted by transfecting 3 x 104 DF-1 cells in 24-well plate with 50 ng TRIM expressing plasmids, 200 ng of ALV vector lacking the envelope protein (plasmid DASBP-GFP, a gift from Stephen Hughes, NCI Frederick, MD) and 50 ng of plasmid expressing ecotropic Friend MLV envelope protein (pcDNA3-FrEnv) [33]. 48 h after transfection, the released virus infectivity was measured by applying two dilutions of the culture supernatants differing by 10-fold onto target cells (DFJ8 for MLV and ALV; HEK293 or TZMbl cells for HIV) in presence of 5 mug/ml of polybrene. GFP-positive cells were enumerated after additional 36-48 h as above. For measuring viral gene expression, the mean fluorescence intensity (MFI) of GFP in the transfected producer cells (48 h after transfection) was estimated using FACS (Becton Dickinson). Fold inhibition in viral gene expression was calculated using the ratio of GFP MFI in cells transfected with vector to those expressing TRIM. The maximum variability between control samples in the absence of TRIM proteins was approximately2-fold. The cut-off value of 6 applied in Figure 3 was the derived from 2 plus two times the standard deviations (confidence value of 95%) of 2.
###end p 87
###begin p 88
###xml 39 42 <span type="species:ncbi:11786">MLV</span>
###xml 55 58 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 429 432 <span type="species:ncbi:11786">MLV</span>
###xml 493 496 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
To measure the release of Gag (p30 for MLV and p24 for HIV) a parallel experiment as described above was conducted in triplicates. 48 h after transfection the culture supernatants from triplicate wells were combined and viruses sedimented at 12,000 x g in a microcentrifuge for 2 h. The resulting 12,000 g pellet was solubilized in SDS gel loading buffer and resolved on SDS-10% PAGE followed by western blot using antibodies to MLV capsid and Env (p30 & gp70; Quality Biotech, Camden, NJ) or HIV capsid (p24; obtained through the AIDS Research and Reference Reagent Program, NIH from Dr. Michael H. Malim.)
###end p 88
###begin title 89
Cell viability, apoptosis, and gene expression assays.
###end title 89
###begin p 90
###xml 439 442 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
Cell viability and Caspase 3/7 activity was measured sequentially for the same samples 48 h after transfection of 50 ng TRIM-expressing construct in HEK 293 cells using CellTiter-Bluetrade mark Cell Viability and Caspase-Glo 3/7 Assay System (Promega Corp.) according to manufacturer's recommendations. To measure the effect on cellular gene expression due to transient expression of TRIM proteins, 10 ng of plasmid expressing GFP under a CMV promoter was co-transfected with 50 ng of TRIM encoding plasmids in HEK293 cells. 48 h later the MFI of GFP and fold inhibitions were calculated as above.
###end p 90
###begin title 91
Viral entry and release assays in RNAi treated cells.
###end title 91
###begin p 92
###xml 6 7 6 7 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 444 447 <span type="species:ncbi:11786">MLV</span>
###xml 452 455 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 798 801 <span type="species:ncbi:11786">MLV</span>
###xml 906 911 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1066 1069 <span type="species:ncbi:11786">MLV</span>
###xml 1090 1093 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1109 1112 <span type="species:ncbi:11786">MLV</span>
###xml 1197 1200 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
2 x 105 HeLa or HEK293 cells in 48 well plates were transfected with 80 nM TRIM-specific siRNA smartpool (Dharmacon Inc) or control siRNA (Dharmacon Inc, #D-001210-01) using Lipofectamine 2000 (Invitrogen, CA). After 4 h the medium was changed and after additional 20 h the cells were split 1:4 into 4 wells of a 48 well plate. For entry assays, 36 h post-transfection, the cells were challenged as above with VSV-G pseudotyped reporter N-, NB-MLV and HIV at two concentrations of virus differing by 2-fold. After additional 24 h the cells were harvested, fixed and analyzed by FACS. For virus release assays, 30 h after first siRNA transfection, cells were transfected again with 80 nM TRIM-specific siRNA smartpool or control siRNA together with either 200 ng plasmid encoding full length Friend MLV genome carrying a GFP insertion into the envelope protein or 100ng of full length replication competent HIV-1 plasmid pNL4-3 (AIDS Research and Reference Reagent Program). After an additional 48 h, the culture supernatants were harvested and applied onto DFJ8 for MLV and TZMbl cells for HIV titration. For MLV, DFJ8 cells were harvested 48 h after infection and analyzed by FACS as before. For HIV, 48 h after infection, TZMBL cells were lysed and luciferase activity measured using a Luminometer (Turner Biosystems). Fold increase in entry or release was calculated using a ratio of the percent GFP positive cells or luciferase activity (measured as relative light units) from experimental samples transfected with TRIM specific siRNA and those transfected with control siRNA.
###end p 92
###begin title 93
TRIM specific siRNA used in the study.
###end title 93
###begin p 94
###xml 75 79 75 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">plus</italic>
###xml 1127 1128 1127 1128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040016-b008">8</xref>
###xml 24 29 <span type="species:ncbi:9606">human</span>
###xml 1032 1037 <span type="species:ncbi:9606">human</span>
###xml 1245 1248 <span type="species:ncbi:11786">MLV</span>
Silencing of endogenous human TRIM proteins was carried out using ON-TARGETplus siRNA smart pools (a mix of 4 siRNAs) from Dharmacon, Inc. pre-designed to reduce off-target effects by up to 90%. We routinely obtained 70 to 90% knock down of specific TRIM proteins as assessed by monitoring the levels of transiently expressed TRIM-GFP 36 h post-transfection. The sense sequences of siRNAs targeting (1) TRIM11 were #1: AG GCGAAGCUGGAGAAGUCUU, #2: GAGCUGAUC CUGUCUGAAGUU, #3: UCACUGCUA UUCAUCUUUCUU, #4: GGACAGCCCAGAGCGCU UUUU; (2) TRIM15 were #1: GGGAGAAACUUACUGCGAGUU, #2: GCGAGAACGAUGCCG AGUUUU, #3: CCCUGAAGGUGGUCCAUGAUU, #4: GCAGAACCACAGACGGCUUUU; (3) TRIM25 were #1: CGGAACA GUUAGUGGAUUUUU, #2: CAACAAGAAUACACGGAA AUU, #3: GCGGAUGACUGCAAACAGAUU, #4: GGGAUGAGUUCGAGUUUCUUU; (4) TRIM31 were #1: GGAGAAGAAUU UCCUGCUAUU, #2: GGAAGAACGCAAUCAGGUU UU, #3: AAUUUGAACUCCUGCAUCAUU, #4: CCACAAAUCCCAUAAUGUCUU; (5) TRIM62 were #1: CUACAAUGCUGAUGACAUGUU, #2: GCGAGAAGUUCCCUGGCAAUU, #3: AGACCAACCUCACAUAUGAUU, #4: GACCAAGUCUUCCACCAAGUU. For human TRIM5, the sequences of the siRNA smart pool from Dharmacon were as previously reported [8]. TRIM5 silencing using this smart pool resulted in a approximately4-fold and approximately50-fold enhancement of N-MLV entry in HEK293 and HeLa cells, respectively.
###end p 94
###begin title 95
Data analysis.
###end title 95
###begin p 96
###xml 235 237 235 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040016-b043">43</xref>
For easy interpretation of the screen we used scatter plots generated using Excel. Fold inhibitions for the two parameters compared were plotted against each other in log scale. Java TREEVIEW was used to represent data in color codes [43]. The input fold inhibition values obtained as described in previous sections were log2 transformed to obtain positive (inhibition, shades of red) and negative (enhancement, shades of green) values prior to data analysis using TREEVIEW.
###end p 96
###begin title 97
Co-immunoprecipitation analysis.
###end title 97
###begin p 98
###xml 187 190 <span type="species:ncbi:11786">MLV</span>
###xml 262 265 <span type="species:ncbi:11786">MLV</span>
###xml 721 724 <span type="species:ncbi:11786">MLV</span>
###xml 802 806 <span type="species:ncbi:9925">goat</span>
HEK293 cells were transfected as above with 50 ng of plasmids encoding TRIM15 derivatives with C-terminal YFP fusions or untagged TRIM15 and 200 ng of plasmid encoding full length Friend MLV genome carrying a GFP insertion into the envelope protein or 100 ng of MLV Gag-GFP. 48 h post-transfection, the cells were lysed using triple detergent lysis buffer (TDLB, 100 mM Tris [pH 8.0], 1% Triton-X-100, 0.5% sodium deoxycholate, 0.2% sodium dodecyl sulphate, 150 mM NaCl). The nuclei and undissolved cellular components were removed by centrifugation at 12,000 x g for 30 minutes in a microcentrifuge. The clarified 12,000 x g supernatant was used for immunoprecipitation using protein-G beads prebound with antibodies to MLV capsid (Quality Biotech, Camden, NJ) or TRIM15 (Abcam, Boston, MA) raised in goat or isotype specific antibodies. The immunoprecipitates were washed three times with TDLB and analyzed using SDS-10%-PAGE followed by western blot using antibodies to GFP.
###end p 98
###begin title 99
Imaging.
###end title 99
###begin p 100
###xml 109 111 109 111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040016-b033">33</xref>
###xml 40 43 <span type="species:ncbi:11786">MLV</span>
###xml 48 51 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 127 130 <span type="species:ncbi:11786">MLV</span>
###xml 185 188 <span type="species:ncbi:11786">MLV</span>
###xml 323 326 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 334 337 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
The generation of fluorescently labeled MLV and HIV virions using Gag-GFP proteins was previously described [33]. To visualize MLV Gag and TRIM15 in HEK293 cells, plasmids encoding for MLV Gag-CFP (50 ng), replication competent MoMLV (200 ng) and TRIM15-YFP (10 ng) were co-transfected. To perform a similar experiment for HIV, 50 ng HIV Gag-YFP was co-transfected with 10 ng TRIM15-CFP. 24 h later, cells were fixed and the CFP and YFP channels monitored using the 60x oil objective (NA 1.4) of a Nikon TE2000 inverted wide-field microscope. To monitor TRIM11 and TRIM5, HEK293 cells were transfected with 5 ng TRIM11-YFP together with 50 ng TRIM5-CFP and cells imaged 24 h post-transfection using the 60x oil Nikon objective (NA 1.4) and an Improvision spinning disc confocal microscope.
###end p 100
###begin title 101
Reverse-transcription PCR for detection of endogenous expressed TRIMs.
###end title 101
###begin p 102
Total RNA was extracted from HEK293 and HeLa cells using PrepEase RNA extraction kit (USB), which has an on-column DNAse treatment step. The RNA was reverse transcribed with anchored oligodT using Reverse-iT first strand synthesis kit (ABgene). The cDNA was then used to check presence TRIM-specific sequences by PCR using appropriate primer pairs. Control reactions which used plain RNA for PCR amplification did not yield any products (data not shown). Specific primer pairs used for amplifications were obtained from Primer Bank database and sequences can be found at .
###end p 102
###begin title 103
Supporting Information
###end title 103
###begin title 104
###xml 57 60 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
Effects of TRIM Protein Expression on Cell Viability and CMV Promoter Activity
###end title 104
###begin p 105
(A) The effect of TRIM protein expression in HEK293 cells using 50 ng of TRIM-expressing constructs in a 24 well on the induction of apoptosis was monitored 48 h post-transfection using a caspase 3/7 activity assay.
###end p 105
###begin p 106
(B) An assay as in (A) was performed to measure the effects of TRIM protein expression on cell viability using the ability of cells to convert resazurin into resorufin.
###end p 106
###begin p 107
###xml 92 95 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
(C) The effects of TRIM protein expression in HEK293 cells as in (A) on the activity of the CMV promoter were tested by measuring GFP fluorescence of the plasmid pEGFP-N1. For TRIM11 proteins, the transfection of 10 ng reduced pleiotropic effects on transcription.
###end p 107
###begin p 108
###xml 47 52 <span type="species:ncbi:10090">mouse</span>
###xml 100 103 <span type="species:ncbi:10116">rat</span>
###xml 156 159 <span type="species:ncbi:9913">cow</span>
###xml 177 180 <span type="species:ncbi:9823">pig</span>
###xml 195 200 <span type="species:ncbi:9606">human</span>
(D) Sequence comparison of the B30.2 domain of mouse TRIM30 in comparison to its closest homologues rat TRIM30 (68% identity), the TRIM5 like proteins from cow 505265 (48%) and pig 733579 (47%), human TRIM5 (47%), and rhesus TRIM5 (45%).
###end p 108
###begin p 109
(1.3 MB TIF)
###end p 109
###begin p 110
Click here for additional data file.
###end p 110
###begin title 111
TRIM Proteins Interfere with Retroviral Release
###end title 111
###begin p 112
###xml 197 205 197 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0040016-g003">Figure 3</xref>
###xml 4 7 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 149 152 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
(A) HIV p24 capsid released into the culture supernatant from HEK293 cells expressing indicated TRIM proteins. Effects of TRIM protein expression on HIV release and viral gene expression are as in Figure 3B.
###end p 112
###begin p 113
###xml 94 102 94 102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0040016-g003">Figure 3</xref>
###xml 33 36 <span type="species:ncbi:11786">MLV</span>
(B) TRIM proteins interfere with MLV release in a dose dependent fashion. An experiment as in Figure 3C was performed with increasing amounts of transfected plasmids encoding TRIM proteins.
###end p 113
###begin p 114
###xml 4 7 <span type="species:ncbi:11786">MLV</span>
(C) MLV p30 capsid and gp70 Env released into the culture supernatant from HEK293 cells expressing indicated TRIM proteins.
###end p 114
###begin p 115
###xml 24 32 24 32 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0040016-g003">Figure 3</xref>
###xml 94 97 <span type="species:ncbi:11864?0.898989898989899">ALV</span>
(D) An experiment as in Figure 3 was performed to determine TRIM proteins that interfere with ALV release in DF-1 cells.
###end p 115
###begin p 116
(3.7 MB TIF)
###end p 116
###begin p 117
Click here for additional data file.
###end p 117
###begin title 118
Endogenous Expression and Silencing of TRIM Proteins Expressed in HEK293 and HeLa Cells
###end title 118
###begin p 119
(A) Reverse transcriptase PCR for the presence of indicated TRIM mRNA in HEK293 and HeLa cells.
###end p 119
###begin p 120
(B) Western blot using GFP antibodies for indicated TRIM-YFP fusion proteins expressed in the presence of control (con) or specific siRNA (sp). Protein loads were monitored using antibodies against actin.
###end p 120
###begin p 121
(1.9 MB TIF)
###end p 121
###begin p 122
Click here for additional data file.
###end p 122
###begin p 123
We are grateful to Germana Meroni for sharing TRIM expression constructs. We thank Joseph Sodroski, Greg Towers, Jonathan Stoye, Stephen Hughes, Alan Rein, and the AIDS Research and Reference Reagent Program for plasmids and reagents; Nathan Sherer, Priti Kumar, and Brett Lindenbach for critical reading of the manuscript; and Ilker Oztop for assistance.
###end p 123
###begin title 124
Abbreviations
###end title 124
###begin p 125
###xml 0 20 <span type="species:ncbi:11946">avian leukemia virus</span>
avian leukemia virus
###end p 125
###begin p 126
green fluorescent protein
###end p 126
###begin p 127
###xml 0 28 <span type="species:ncbi:12721">human immunodeficiency virus</span>
human immunodeficiency virus
###end p 127
###begin p 128
###xml 0 21 <span type="species:ncbi:11786">murine leukemia virus</span>
murine leukemia virus
###end p 128
###begin p 129
TRIpartite interaction Motif
###end p 129
###begin title 130
References
###end title 130
###begin article-title 131
Host factors exploited by retroviruses
###end article-title 131
###begin article-title 132
TRIM family proteins: retroviral restriction and antiviral defence
###end article-title 132
###begin article-title 133
Post-entry restriction of retroviral infections
###end article-title 133
###begin article-title 134
Intrinsic immunity: a front-line defense against viral attack
###end article-title 134
###begin article-title 135
###xml 43 48 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Cyclophilin, TRIM5, and innate immunity to HIV-1
###end article-title 135
###begin article-title 136
###xml 26 31 <span type="species:ncbi:10090">mouse</span>
Positional cloning of the mouse retrovirus restriction gene Fv1
###end article-title 136
###begin article-title 137
###xml 61 84 <span type="species:ncbi:11786">murine leukemia viruses</span>
A major genetic locus affecting resistance to infection with murine leukemia viruses. IV. Dose-response relationships in Fv-1-sensitive and resistant cell cultures
###end article-title 137
###begin article-title 138
###xml 52 57 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys
###end article-title 138
###begin article-title 139
###xml 53 63 <span type="species:ncbi:9505">owl monkey</span>
###xml 78 83 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Cyclophilin A retrotransposition into TRIM5 explains owl monkey resistance to HIV-1
###end article-title 139
###begin article-title 140
Retrovirus resistance factors Ref1 and Lv1 are species-specific variants of TRIM5alpha
###end article-title 140
###begin article-title 141
###xml 4 9 <span type="species:ncbi:9606">human</span>
###xml 14 34 <span type="species:ncbi:9534">African green monkey</span>
The human and African green monkey TRIM5alpha genes encode Ref1 and Lv1 retroviral restriction factor activities
###end article-title 141
###begin article-title 142
###xml 34 39 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 44 65 <span type="species:ncbi:11786">murine leukemia virus</span>
Trim5alpha protein restricts both HIV-1 and murine leukemia virus
###end article-title 142
###begin article-title 143
###xml 4 9 <span type="species:ncbi:9606">human</span>
###xml 87 108 <span type="species:ncbi:11786">murine leukemia virus</span>
The human TRIM5alpha restriction factor mediates accelerated uncoating of the N-tropic murine leukemia virus capsid
###end article-title 143
###begin article-title 144
Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5alpha restriction factor
###end article-title 144
###begin article-title 145
TRIM5alpha selectively binds a restriction-sensitive retroviral capsid
###end article-title 145
###begin article-title 146
The tripartite motif family identifies cell compartments
###end article-title 146
###begin article-title 147
TRIM/RBCC, a novel class of 'single protein RING finger' E3 ubiquitin ligases
###end article-title 147
###begin article-title 148
PML and PML nuclear bodies: Implications in antiviral defence
###end article-title 148
###begin article-title 149
TRIM5{alpha} Cytoplasmic Bodies Are Highly Dynamic Structures
###end article-title 149
###begin article-title 150
Subclassification of the RBCC/TRIM superfamily reveals a novel motif necessary for microtubule binding
###end article-title 150
###begin article-title 151
MID2, a homologue of the Opitz syndrome gene MID1: similarities in subcellular localization and differences in expression during development
###end article-title 151
###begin article-title 152
Functional characterization of the Opitz syndrome gene product (midin): evidence for homodimerization and association with microtubules throughout the cell cycle
###end article-title 152
###begin article-title 153
The Opitz syndrome gene product, MID1, associates with microtubules
###end article-title 153
###begin article-title 154
###xml 58 79 <span type="species:ncbi:11786">murine leukemia virus</span>
TRIM28 mediates primer binding site-targeted silencing of murine leukemia virus in embryonic cells
###end article-title 154
###begin article-title 155
###xml 68 103 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Molecular cloning of a new interferon-induced factor that represses human immunodeficiency virus type 1 long terminal repeat expression
###end article-title 155
###begin article-title 156
###xml 26 31 <span type="species:ncbi:9606">human</span>
Identification of a novel human zinc finger protein that specifically interacts with the activation domain of lentiviral Tat proteins
###end article-title 156
###begin article-title 157
TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-I-mediated antiviral activity
###end article-title 157
###begin article-title 158
Control of viral infectivity by tripartite motif proteins
###end article-title 158
###begin article-title 159
Genetic mapping of the cloned subgroup A avian sarcoma and leukosis virus receptor gene to the TVA locus
###end article-title 159
###begin article-title 160
###xml 62 66 <span type="species:ncbi:9913">cows</span>
Evolution of a cytoplasmic tripartite motif (TRIM) protein in cows that restricts retroviral infection
###end article-title 160
###begin article-title 161
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human tripartite motif 5alpha domains responsible for retrovirus restriction activity and specificity
###end article-title 161
###begin article-title 162
Positive selection of primate TRIM5alpha identifies a critical species-specific retroviral restriction domain
###end article-title 162
###begin article-title 163
Visualization of retroviral replication in living cells reveals budding into multivesicular bodies
###end article-title 163
###begin article-title 164
Actin- and myosin-driven movement of viruses along filopodia precedes their entry into cells
###end article-title 164
###begin article-title 165
The RBCC gene RFP2 (Leu5) encodes a novel transmembrane E3 ubiquitin ligase involved in ERAD
###end article-title 165
###begin article-title 166
###xml 14 34 <span type="species:ncbi:11864">avian leukosis virus</span>
###xml 106 134 <span type="species:ncbi:12721">human immunodeficiency virus</span>
Production of avian leukosis virus particles in mammalian cells can be mediated by the interaction of the human immunodeficiency virus protein Rev and the Rev-responsive element
###end article-title 166
###begin article-title 167
###xml 0 13 <span type="species:ncbi:9544">Rhesus monkey</span>
###xml 35 40 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Rhesus monkey TRIM5alpha restricts HIV-1 production through rapid degradation of viral Gag polyproteins
###end article-title 167
###begin article-title 168
TRIM11 binds to and destabilizes a key component of the activator-mediated cofactor complex (ARC105) through the ubiquitin-proteasome system
###end article-title 168
###begin article-title 169
A tripartite motif protein TRIM11 binds and destabilizes Humanin, a neuroprotective peptide against Alzheimer's disease-relevant insults
###end article-title 169
###begin article-title 170
Retroviruses can establish filopodial bridges for efficient cell-to-cell transmission
###end article-title 170
###begin article-title 171
Retroviral entry mediated by receptor priming and low pH triggering of an envelope glycoprotein
###end article-title 171
###begin article-title 172
A conserved mechanism of retrovirus restriction in mammals
###end article-title 172
###begin article-title 173
Java Treeview-extensible visualization of microarray data
###end article-title 173
###begin p 174
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Author contributions.</bold>
Author contributions. PDU, BDQ, and WM designed the study. PDU and BDQ performed all experiments with some assistance from WTC and JML. PDU and WM wrote the manuscript.
###end p 174
###begin p 175
###xml 0 8 0 8 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding.</bold>
Funding. This work was supported by the National Institutes of Health (NIH) grants RO1CA098727 and R21 AI065284 to WM and an Anna Fuller Fellowship in Cancer Research to PDU.
###end p 175
###begin p 176
###xml 0 20 0 20 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing interests.</bold>
Competing interests. The authors have declared that no competing interests exist.
###end p 176

